# Package: BayesianTrial (via r-universe)

November 19, 2026

**Title** Bayesian Decision-Making for Clinical Trials

**Version** 0.1.0

**Maintainer** Jiangyan Zhao <zhaojy2017@126.com>

**Description** Provides tools for Bayesian decision-making in single-arm phase II clinical trials with binary efficacy endpoints. Uses Beta-binomial models to calculate posterior probabilities that the response rate exceeds a prespecified reference value and to estimate predictive probabilities of meeting final-analysis success criteria. Evaluates the frequentist operating characteristics of two-stage designs with posterior-probability-based stopping rules, including type I error rates, statistical power, and probabilities of early stopping for efficacy or futility, using Monte Carlo simulation. For methodological background, see Thall and Simon (1994) <doi:10.2307/2533377> and Lee and Liu (2008) <doi:10.1177/1740774508089279>.

**License** GPL (>= 3)

**URL** https://github.com/Jiangyan-Zhao/BayesianTrial

**BugReports** https://github.com/Jiangyan-Zhao/BayesianTrial/issues

**Encoding** UTF-8

**NeedsCompilation** no

**Depends** R (>= 3.5.0)

**Imports** stats

**Suggests** knitr, rmarkdown, testthat (>= 3.0.0)

**VignetteBuilder** knitr, rmarkdown

**Config/roxygen2/version** 8.1.0

**Config/testthat/edition** 3

**Author** Jiangyan Zhao [cre, aut], Rongji Mu [aut, cph]

**Repository** https://cran.r-universe.dev

**Date/Publication** 2026-11-19 11:30:24 UTC

**RemoteUrl** https://github.com/cran/BayesianTrial

**RemoteRef** HEAD

**RemoteSha** 9d3cc2f95e38a93cb02d4be11173a8e7080897a7

# Contents

oc_singlearm_binary . . . . . 2
posterior_predictive_singlearm_binary . . . . . 4

**Index** **7**

---

`oc_singlearm_binary` *Operating Characteristics of a Two-Stage Single-Arm Phase II Trial*

---

## Description

Evaluates the operating characteristics of a two-stage single-arm phase II trial with a binary efficacy endpoint and prespecified posterior-probability stopping rules. Monte Carlo simulation is used to estimate the probability of trial success and early stopping probabilities for efficacy and futility.

## Usage

```
oc_singlearm_binary(
  theta_true,
  n_current,
  N_total,
  alpha0 = 0.2,
  beta0 = 0.8,
  theta0_null = 0.2,
  gamma_early = 0.98,
  gamma_futility = 0.5,
  gamma_final = 0.95,
  ntrial = 10000,
  seed = 666
)
```

## Arguments

| | |
|---|---|
| `theta_true` | Assumed true treatment response rate for generating trial outcomes; a probability between 0 and 1. Specify the null-scenario rate to assess the type I error rate or a clinically promising alternative rate to assess power. |
| `n_current` | Planned number of patients with evaluable outcomes at the single interim analysis; a non-negative integer not exceeding `N_total`. A conventional two-stage design requires `0 < n_current < N_total`. |
| `N_total` | Planned maximum number of evaluable patients; a non-negative integer at least as large as `n_current`. |

| | |
|---|---|
| `alpha0`, `beta0` | Positive, finite shape parameters of the Beta prior for the response rate. Their sum must also be finite. |
| `theta0_null` | Prespecified unacceptable or historical reference response rate used as the primary efficacy benchmark; a probability between 0 and 1. |
| `gamma_early` | Interim posterior probability cutoff for early declaration of efficacy; a probability between 0 and 1. An early positive result is declared if the posterior probability of exceeding `theta0_null` is strictly greater than this cutoff. |
| `gamma_futility` | Interim posterior probability cutoff for stopping due to futility; a probability between 0 and 1 and strictly less than `gamma_early`. Futility stopping occurs if the posterior probability of exceeding `theta0_null` is less than or equal to this cutoff. This is not a predictive probability cutoff. |
| `gamma_final` | Posterior probability cutoff for declaring a positive result at the final analysis if the trial continues; a probability between 0 and 1. |
| `ntrial` | Positive integer number of independently simulated trials. |
| `seed` | Optional integer seed for reproducibility. |

## Value

A named list containing:

**power_null_post** Estimated overall probability of declaring a positive trial result, including early efficacy stopping. Interpreted as type I error probability under a null scenario or as power under a specified alternative.

**early_stop_rate_futility** Estimated probability of stopping the trial at the interim analysis for futility.

**early_stop_rate_efficacy** Estimated probability of stopping the trial at the interim analysis for efficacy.

## References

Zhao, J., and Mu, R. (2026). Introduction to Bayesian Decision Method and Its Application in Medical Research. Manuscript in preparation (in Chinese).

Thall, P. F., and Simon, R. M. (1994). Practical Bayesian guidelines for phase IIB clinical trials. *Biometrics*, 50, 337–349. doi:10.2307/2533377.

Lee, J. J., and Liu, D. D. (2008). A predictive probability design for phase II cancer clinical trials. *Clinical Trials*, 5, 93–106. doi:10.1177/1740774508089279.

## See Also

`posterior_predictive_singlearm_binary`

## Examples

```
null_oc <- oc_singlearm_binary(
  theta_true = 0.20, n_current = 20, N_total = 40
)
alternative_oc <- oc_singlearm_binary(
```

```
  theta_true = 0.40, n_current = 20, N_total = 40
)
null_oc$power_null_post  # Type I error probability at the null rate
alternative_oc$power_null_post  # Power at the alternative rate
```

---

`posterior_predictive_singlearm_binary`
*Posterior and Predictive Probabilities for a Single-Arm Phase II Trial*

---

## Description

Calculates posterior summaries of the treatment response rate and predictive probabilities of meeting prespecified final-analysis efficacy criteria in single-arm phase II trials with binary endpoints.

## Usage

```
posterior_predictive_singlearm_binary(
  x_obs,
  n_current,
  N_total,
  alpha0 = 0.2,
  beta0 = 0.8,
  theta0_null = 0.2,
  theta0_clin = 0.4,
  gamma_final = 0.95,
  gamma_clin_final = 0.9,
  S = 10000,
  type = c("posterior", "predictive", "both"),
  seed = 666
)
```

## Arguments

| | |
|---|---|
| `x_obs` | Number of observed responses among `n_current` patients; a non-negative integer no greater than `n_current`. |
| `n_current` | Number of patients with evaluable outcomes at the current analysis; a non-negative integer no greater than `N_total`. |
| `N_total` | Planned maximum number of patients with evaluable outcomes; a non-negative integer at least as large as `n_current`. |
| `alpha0`, `beta0` | Positive shape parameters of the Beta prior for the response rate. |
| `theta0_null` | Prespecified historical reference or unacceptable response rate; a probability between 0 and 1. |
| `theta0_clin` | Clinically meaningful target response rate for a supplementary predictive assessment; a probability between 0 and 1. |
| `gamma_final` | Final posterior probability threshold for trial success relative to `theta0_null`; a probability between 0 and 1. |

`gamma_clin_final`
: Final posterior probability threshold for the supplementary criterion relative to `theta0_clin`; a probability between 0 and 1.

`S`
: Positive integer number of Monte Carlo replications used to estimate predictive probabilities.

`type`
: Results to return: `"posterior"` (default), `"predictive"`, or `"both"`.

`seed`
: Optional integer seed for reproducibility.

## Value

A named list containing the components specified by `type`. The default returns posterior summaries; `"predictive"` returns predictive probabilities; `"both"` returns all components:

**posterior** Shape parameters `alpha` and `beta` of the current Beta posterior.

**posterior_mean** Posterior mean of the response rate.

**posterior_sd** Posterior standard deviation of the response rate.

**p_null** Posterior probability that the response rate exceeds `theta0_null`.

**ppos_null** Predictive probability of meeting the final efficacy criterion defined by `theta0_null` and `gamma_final`.

**ppos_clin** Predictive probability of meeting the supplementary criterion defined by `theta0_clin` and `gamma_clin_final`.

Predictive probabilities are estimated by Monte Carlo simulation, conditional on the observed data and completion of the planned sample size `N_total`.

## References

Zhao, J., and Mu, R. (2026). Introduction to Bayesian Decision Method and Its Application in Medical Research. Manuscript in preparation (in Chinese).

Thall, P. F., and Simon, R. M. (1994). Practical Bayesian guidelines for phase IIB clinical trials. *Biometrics*, 50, 337–349. doi:10.2307/2533377.

Lee, J. J., and Liu, D. D. (2008). A predictive probability design for phase II cancer clinical trials. *Clinical Trials*, 5, 93–106. doi:10.1177/1740774508089279.

## See Also

`oc_singlearm_binary`

## Examples

```
posterior <- posterior_predictive_singlearm_binary(
  x_obs = 9, n_current = 20, N_total = 40
)
posterior$p_null

predictive <- posterior_predictive_singlearm_binary(
  x_obs = 9, n_current = 20, N_total = 40,
  type = "predictive"
```

```
)
predictive$ppos_null

both <- posterior_predictive_singlearm_binary(
  x_obs = 9, n_current = 20, N_total = 40,
  type = "both"
)
both
```

# Index

oc_singlearm_binary, 2, *5*

posterior_predictive_singlearm_binary, *3*, 4